Senior Manager Complaint Vigilance

From composition to causation: why science-led beauty is reshaping the ingredients industry. Something is shifting in the way the beauty industry talks about science. For years, efficacy was communicated through concentration: percentages on pack, hero actives in the product name, long ingredient lists that signaled effort and investment. That approach is no longer enough. Consumers are asking sharper questions. Regulators are tightening what can be claimed. And brands are expecting their suppliers and formulators to come to the table with more than specifications. The Bar Has Moved Listing what is in a formula is no longer sufficient to prove it works. This is not a passing trend; it is a fundamental shift in what the market now demands. According to Euromonitor's 2026 Global Beauty Outlook, 49% of consumers would pay a premium for beauty products with a scientific formulation, and dermocosmetics retail sales posted double-digit growth across all regions between 2020 and 2024 [1]. Consumers want proof, and they are willing to pay for it. For suppliers and formulators, this means the work of building a credible efficacy case starts much earlier in the development process. The brands navigating this transition most successfully are building the scientific foundation first, then communicating the science after. Where the Science Is Converging Three areas of scientific progress are coming together to change what is possible in personal care formulation, and each one is raising the bar across the value chain. Advances in skin biology are giving formulators a more precise map of how skin actually behaves. Research into aging biomarkers, epigenetics, and barrier science has moved well beyond surface observation. Visible results remain important, but the conversation is increasingly moving toward what is actually happening in the skin, and why. At the same time, delivery science is maturing within the cosmetics field. Transdermal technologies, precision targeting, and bioavailability optimization are approaches developed in pharmaceutical R&D that are being adopted more widely in formulation work. Where an active is delivered in the skin, at what concentration, and over what timeframe is increasingly factored into formulation decisions. The third shift is in how efficacy is evaluated. Clinical validation, once associated mainly with dermo-cosmetic or prescription-adjacent products, is becoming more common across the broader personal care market. At the 2026 American Academy of Dermatology Annual Meeting, Kenvue presented clinical research developed alongside dermatologists and trichologists across its Neutrogena and Aveeno brands, and announced a first-ever partnership with Boards University to embed formulation science education into dermatology residency programs [2]. This reflects how quickly clinical collaboration is becoming the norm rather than a distinction. For ingredient suppliers, the implication is clear. In formulator conversations, the discussion now routinely covers mechanisms, biological targets, and clinical endpoints. Cross-Sector Innovation Is Compressing the Timeline Synthetic biology is opening up new ways to design and produce cosmetic ingredients, including precision fermentation and AI-assisted molecule development. Actives that were previously difficult to obtain at scale, or too costly to extract from natural sources, can now be produced more consistently, with stronger safety profiles and a lower environmental footprint. According to Frost & Sullivan, biotechnological processes are actively reshaping beauty innovation, with bioidentical cosmetic actives emerging as a significant growth area across the ingredients market [3]. The growing overlap between cosmetics and pharmaceutical science is also having an impact. Target mechanism research, biomarker screening, and structured clinical validation, developed in drug discovery, are being applied to personal care product development. And AI tools are being used across R&D functions for ingredient selection, stability testing, and performance modeling, reducing development timelines [4]. Science that was considered advanced a few years ago is now becoming standard industry practice. The New Cost of Entry These changes are being felt most directly by ingredient suppliers and formulators. A technical data sheet is no longer sufficient on its own. Brand clients are asking harder questions about how ingredients work at a biological level, and those questions are coming up earlier in the conversation. For formulators, delivery science, regulatory compliance, and efficacy substantiation now need to be considered together. A formulation that performs well in testing but lacks the documentation to support a claim can be a commercial liability. One that is substantiated but cannot be delivered effectively to its target site is scientifically incomplete. The science must hold together: from the choice of ingredient, through formulation, to the evidence behind the final claim. Strong claims documentation is increasingly a commercial advantage. Companies that have invested in building a solid evidence base are better positioned to enter new markets with confidence. There is still time to build these capabilities before they become standard requirements. But that window is getting smaller. PCHi: The Conversation Starts Here Asia Pacific is where many of these pressures are most visible. Consumer demands are rising, regulators are tightening requirements, and the region's dense ingredient supply chain means that decisions made here tend to have wider influence. What becomes standard practice in this part of the world often shapes how the rest of the global industry follows. PCHi 2027 will be where the industry gathers to work through these challenges together - bringing formulators, suppliers, researchers, and brand developers into the same space, across seven halls of ingredient and formulation innovation, a technical conference, and the PCHi Fountain Awards. The next edition of PCHi will take place from February 24-26, 2027, at the China Import and Export Fair Complex in Guangzhou. For more information, please visit www.pchi-china.com/en. Industry professionals are encouraged to plan ahead and pre-register at https://bit.ly/PCHi2027PreReg to be part of the industry's most anticipated gathering of the year. [1] BeautyMatter, The Value of Beauty: Euromonitor's 2026 Global Beauty Outlook. Available at: https://beautymatter.com/articles/euromonitors-2026-globalbeauty-outlook [2] Kenvue, Neutrogena(R), Aveeno(R) and Rogaine(R) Debut New Dermatology Research & Clinical Skincare Innovations at AAD 2026. Available at: https://www.kenvue.com/media/aad-2026-dermatology-research [3] Frost & Sullivan, Growth Opportunities in Bio-identical Cosmetic Actives: Biotechnological Processes Transform Beauty Innovation, May 2026. Available at: https://www.frost.com/growth-opportunity-news/techvision/growth-opportunities-in-bio-identical-cosmetic-actives-biotechnological-processes-transformbeauty-innovation-tnv02_tg02_growthoppinbio-identicalcosmeticactives_tgc_db67_apr26-_cim-sn/ [4] NYSCC, Artificial Intelligence - Delivering Transformational Innovation in the Beauty and Personal Care Industry, March 2026. Available at: https://nyscc.org/blog/artificial-intelligence-delivering-transformational-innovation-in-the-beauty-and-personal-care-industry/ Picture: Behind every formulation is a scientific case that now needs to be built, not just implied. (Image designed by Magnific) About PCHi The Personal Care and Homecare Ingredients (PCHi) trade show is China's #1 Sourcing Platform for the Global Personal Care Industry. As an innovation-led event, PCHi provides cosmetics, home and personal care manufacturers, ingredients suppliers, cosmetics packaging, machinery and product testing providers from all over the world with a quality platform for ingredients sourcing, gaining insight into global trends, and networking with world-class experts. | WeChat | / |

US FDA approves over-the-counter Tylenol combination pill for pain relief. By Thomson Reuters Jul 24, 2026 | 11:00 AM July 24 (Reuters) - The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's Tylenol with the nonsteroidal anti-inflammatory drug naproxen for up to 12 hours of pain relief. Here are some details: - The pill can be used by adults and children aged 12 and older for headaches, back pain, muscle aches, toothaches, menstrual cramps and minor arthritis pain. - The FDA said the approval aligns with Trump's "The Great Healthcare Plan," a federal effort to make more verified safe pharmaceutical drugs available for over-the-counter purchase. - Each pill contains 325 milligrams of Tylenol and 110 milligrams of naproxen sodium. - Tylenol has been under scrutiny after U.S. health officials raised concerns about an alleged link between Tylenol use during pregnancy and autism. There is no firm scientific evidence of such a link. - The debate has also triggered legal action, as Texas sued Kenvue over alleged failures to warn pregnant consumers, and a U.S. appeals court this month revived more than 500 private lawsuits making similar claims. - Kenvue agreed last November to be acquired by Kleenex tissue maker Kimberly-Clark for more than $40 billion. The transaction is expected to close this year. (Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)

Kenvue streamlines PCR in its packaging with Resycure's data platform. 21 July 2026 Kenvue is using Resycure's digital platform to unlock batch-level traceability, transparent data, consistent quality and more while implementing post-consumer recyclate into its packaging. Kenvue's teams initially underlined recurring challenges as they sought to implement recycled materials into the company's packaging lines. This included batch-to-batch variability across post-consumer recycled materials and differences in visual appearance, including colour consistency. Transparency across supply chain partners was also found to be limited, with many cases requiring disconnected data from at least five different organizations. This made it difficult to identify root causes or validate suspected issues, resulting in slow and manual traceability. Kenvue highlights that these obstacles can lead to delays, inefficiencies, and obstacles to scaling post-consumer recyclate usage in a fast-moving production environment. In its partnership with Kenvue, the company has established a harmonized definition of 'high-quality' post-consumer recyclate from a performance and aesthetic standpoint. All partners, recyclers, converters and internal teams are now expected to work towards the same standard. Now every finished bottle can be linked to a pellet batch, preform run and blow-mould cycle via the Resycure platform. Brands, regulators and recyclers alike can access the information - an outcome set to avoid fragmentation and improve the accuracy and speed of investigations. Ongoing monitoring, analytics, and structured discussions are set to help Kenvue manage the variability of post-consumer recyclate, maintain aesthetic consistency, and address any areas for improvement. Apparently, the collaborative approach has helped Kenvue reduce investigation times by approximately 35% on average. The companies claim to monitor over 100 batches of post-consumer recyclate per quarter, resulting in more consistent visibility and proactive decision-making. "With batch-level data visibility and end-to-end tracking through the Resycure platform, we established clear colour performance standards that can deliver superior aesthetics and consistency for our brands," says Gayatri Keskar, Ph.D., Global Packaging Materials Science leader at Kenvue. "Resycure's team has really helped in coordinating and streamlining the efforts of all companies along the value chain," continues Alberto Axerio, Global Packaging Category senior manager at Kenvue. "Additionally, as brand-owner, their platform is increasing our visibility on the quality and supply chain of our PCR resin." Resycure's QI suite for controlling and optimizing PCR has been nominated for a Sustainability Award under the Digital Transformation category. This year's winners will be announced at an awards ceremony during the Sustainable Packaging Summit, taking place in Utrecht from 10 - 12 November. In other news, Kenvue has partnered with Greyparrot to implement the AI-powered Deepnest platform into its commercial sorting facilities. This is hoped to improve the global recycling for its brand packaging.